Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $5.9 million.

  • Krystal Biotech's Change in Accured Expenses rose 204.69% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 893.15%. This contributed to the annual value of $5.4 million for FY2024, which is 18.28% up from last year.
  • Per Krystal Biotech's latest filing, its Change in Accured Expenses stood at $5.9 million for Q3 2025, which was up 557.26% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Change in Accured Expenses ranged from a high of $7.5 million in Q4 2024 and a low of -$5.2 million during Q1 2024.
  • For the 3-year period, Krystal Biotech's Change in Accured Expenses averaged around $1.7 million, with its median value being $1.9 million (2024).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 629.35% in 2022, then plummeted by 272.03% in 2023.
  • Over the past 5 years, Krystal Biotech's Change in Accured Expenses (Quarterly) stood at -$4.0 million in 2021, then skyrocketed by 153.64% to $2.2 million in 2022, then spiked by 70.75% to $3.7 million in 2023, then spiked by 103.18% to $7.5 million in 2024, then spiked by 204.69% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, -$1.3 million for Q2 2025, and $3.7 million during Q1 2025.